Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Free Cash Flow (2020 - 2025)

Arcutis Biotherapeutics has reported Free Cash Flow over the past 6 years, most recently at $26.2 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $26.2 million for Q4 2025, up 3600.67% from a year ago — trailing twelve months through Dec 2025 was -$6.3 million (up 94.38% YoY), and the annual figure for FY2025 was -$6.3 million, up 94.38%.
  • Free Cash Flow for Q4 2025 was $26.2 million at Arcutis Biotherapeutics, up from -$1.8 million in the prior quarter.
  • Over the last five years, Free Cash Flow for ARQT hit a ceiling of $26.2 million in Q4 2025 and a floor of -$80.4 million in Q1 2023.
  • Median Free Cash Flow over the past 5 years was -$44.6 million (2023), compared with a mean of -$40.0 million.
  • Biggest five-year swings in Free Cash Flow: plummeted 122.11% in 2021 and later surged 3600.67% in 2025.
  • Arcutis Biotherapeutics' Free Cash Flow stood at -$52.0 million in 2021, then crashed by 36.98% to -$71.2 million in 2022, then increased by 20.98% to -$56.2 million in 2023, then soared by 98.67% to -$748000.0 in 2024, then surged by 3600.67% to $26.2 million in 2025.
  • The last three reported values for Free Cash Flow were $26.2 million (Q4 2025), -$1.8 million (Q3 2025), and $246000.0 (Q2 2025) per Business Quant data.